HalioDx, a new company focused on cancer companion diagnostics, is kicking off operations after a management buyout at Qiagen's Marseille subsidiary.
Lancet study finds that Qiagen's Quantiferon estimates lower rate of TB in China than the traditional test
Qiagen pointed to a study in The Lancet showing that its Quantiferon-TB Gold tuberculosis test is more accurate at detecting tuberculosis than the traditional tuberculin skin test, which the company said is overestimating the prevalence of the disease in China.
With its recent acquisition of diagnostics outfit Enzymatics, Dutch Qiagen has gained another strategic partner--the newly formed company ArcherDX, which will focus solely on developing next-generation sequencing products.
Qiagen has been winning critical regulatory approvals for new tests and inking companion diagnostics deals to expand its market reach. The company has exceeded its goal of 250 new placements for its modular molecular testing system in 2014 and is hedging its bets on growth in the coming year.
German Qiagen ($QGEN) is stepping up to help laboratories respond to the ongoing Ebola outbreak in West Africa. The company said it has partnered with Germany's Altona Diagnostics to distribute an Ebola test both in and outside the U.S.
With its sights set on growth, German diagnostics outfit Curetis AG has closed a $18.1 million Series B financing round with new investor Qiagen chipping in.
Hot on the trail of companion diagnostics partnerships, Qiagen is teaming up with pharma bigwig Novartis to develop tests for the company's drug portfolio.
Qiagen beat the Street's expectations during the third quarter, riding high on strong sales of its companion diagnostic products and the continued success of its next-generation tuberculosis blood test.
Genomics England has dropped two-thirds of the candidates to provide variant annotation and clinical interpretation services to the 100,000 Genomes Project after reviewing the first round of responses.
The global companion diagnostics market crossed the billion-dollar threshold in 2013 and is continuing to climb rapidly as healthcare systems tap into the value of testing which patients would benefit most from targeted treatments.